As of 2025-07-11, the Intrinsic Value of Astellas Pharma Inc (4503.T) is 719.16 JPY. This 4503.T valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 1,377.00 JPY, the upside of Astellas Pharma Inc is -47.80%.
The range of the Intrinsic Value is 231.53 - 8,202.37 JPY
Based on its market price of 1,377.00 JPY and our intrinsic valuation, Astellas Pharma Inc (4503.T) is overvalued by 47.80%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 231.53 - 8,202.37 | 719.16 | -47.8% |
| DCF (Growth 10y) | 472.92 - 11,053.53 | 1,123.42 | -18.4% |
| DCF (EBITDA 5y) | 771.22 - 1,110.90 | 977.76 | -29.0% |
| DCF (EBITDA 10y) | 958.27 - 1,437.41 | 1,229.74 | -10.7% |
| Fair Value | 335.37 - 335.37 | 335.37 | -75.65% |
| P/E | 347.52 - 426.80 | 378.94 | -72.5% |
| EV/EBITDA | 692.80 - 1,375.71 | 980.81 | -28.8% |
| EPV | 1,946.78 - 2,757.48 | 2,352.13 | 70.8% |
| DDM - Stable | 400.77 - 3,849.57 | 2,125.17 | 54.3% |
| DDM - Multi | 859.69 - 5,217.23 | 1,377.86 | 0.1% |
| Market Cap (mil) | 2,491,901.80 |
| Beta | 0.44 |
| Outstanding shares (mil) | 1,809.66 |
| Enterprise Value (mil) | 2,491,901.80 |
| Market risk premium | 6.13% |
| Cost of Equity | 6.68% |
| Cost of Debt | 5.00% |
| WACC | 5.95% |